Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Akebia Therapeutics advances vadadustat globally, eyes U.S. launch in 2024

Akebia Therapeutics showcased operational progress and financial stability during the Q2 earnings call, emphasizing vadadustat's global potential.
While facing regulatory challenges and competitive pressures, the company's strategic partnerships and leadership confidence signal growth opportunities.
Analysts' inquiries highlighted areas for improvement, suggesting a need for clearer communication and strategic clarity in key operational areas.
Overall, Akebia remains focused on advancing vadadustat towards potential U.S. approval, positioning for future growth and market success.

Akebia Therapeutics reports strong Q3 earnings and readies for vadadustat launch

Akebia Therapeutics is poised for the potential launch of vadadustat with strong financial performance and a well-prepared commercial infrastructure.
The company faces challenges in pricing strategies and market competition but has opportunities to capture a significant share of the anemia treatment market.
Overall, Akebia Therapeutics remains focused on delivering value to patients and shareholders through vadadustat's potential success in the U.S. market.

Akebia Therapeutics reports successful Vafseo launch, faces revenue challenges

Akebia Therapeutics achieved a successful Vafseo launch exceeding revenue expectations Despite challenges of increased expenses and lower revenues, strong demand for Vafseo is a key strength Opportunities lie in upcoming FDA meeting for Phase III trial and growth potential of Vafseo

Akebia Therapeutics reports record revenue and growth opportunities in Q2

Akebia Therapeutics delivered a strong performance in Q2 2025, marked by record revenue, prescription volume growth, and positive patient outcomes. The company's products, Vafseo and Auryxia, demonstrated market strength and growth potential, supported by expanding access and physician acceptance. While facing challenges such as potential generic competition and trial timelines, Akebia Therapeutics remains well-positioned to capitalize on growth opportunities in the dialysis market.

Akebia Therapeutics reports robust Q3 earnings and plans market expansion

Akebia Therapeutics demonstrated solid financial performance in Q3 2025, driven by VAFSEO and Auryxia, with a focus on revenue growth and market expansion. The company faces challenges in flat demand and operational issues but is actively pursuing opportunities to enhance patient access and drive product demand. Strategies to address challenges and capitalize on opportunities reflect a proactive approach to sustaining growth and maximizing market potential. Overall, Akebia Therapeutics' Q3 earnings call highlights a balanced outlook with a strong foundation for future growth and market success.

Akebia Therapeutics reports solid 2025 performance and outlines growth strategies

Akebia Therapeutics navigated challenges in 2025 to achieve notable revenue milestones and position Vafseo for continued growth. The company's focus on operational efficiency and pipeline expansion underscores a commitment to long-term success and innovation. Analyst inquiries into growth prospects and study outcomes reflect investor interest in the company's strategic direction and product developments.

Akebia Therapeutics reports robust Q1 performance amidst strategic advancements

Akebia Therapeutics demonstrated strong performance and resilience in Q1 2026, driven by Vafseo's success and strategic focus on clinical evidence and pipeline advancement. While facing challenges such as revenue fluctuations and competitive pressures, the company's strengths in product adoption and innovation position them well for future growth. By seizing opportunities in expanding Vafseo adoption, advancing pipeline products, and addressing key analyst inquiries, Akebia can navigate challenges and drive sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.